Urinary neopterin is a valuable tool in monitoring Crohn's disease activity

Inflammatory Bowel Diseases

Volumn 14, Issue 11, 2008, Pages 1548-1554

  Nancey, S ^a,b   Perret Liaudet, A ^c   Moussata, D ^a   Graber, I ^a   Boschetti, G ^a   Renaud, B ^c   Kaiserlian, D ^b   Reimund, J M ^d   Flourie B ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b University Lyon i   (France)

^c CBE   (France)

^d Biology and Innovative Therapeutics for Ovarian Cancers group   (France)

Author keywords

CDA1; Crohn's disease; CRP; Disease activity; Urinary neopterin

Indexed keywords

C REACTIVE PROTEIN; CREATININE; NEOPTERIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; URINALYSIS; URINARY EXCRETION; URINE LEVEL; ADOLESCENT; AGE; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; HOSPITALIZATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MONITORING; PROBABILITY; REFERENCE VALUE; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; URINE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPTERIN; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; URINALYSIS; YOUNG ADULT;

EID: 59249085708     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20510     Document Type: Article

References (39)

1. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
2. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
3. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665-672.
4. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983-989.
5. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-513.
6. Huber C, Fuchs D, Hausen A, et al. Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol. 1983;130:1047-1050.
7. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984;160:310-316.
8. Fuchs D, Hausen A, Reibnegger G, et al. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today. 1988;9:150-155.
9. Kramer A, Wiktor SZ, Fuchs D, et al. Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection. J Acquir Immune Defic Syndr. 1989;2:291-296.
10. Fuchs D, Spira TJ, Hausen A, et al. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem. 1989;35:1746-1749.
11. Wirleitner B, Schroecksnadel K, Winkler C, et al. Neopterin in HIV-1 infection. Mol Immunol. 2005;42:183-194.
12. Margreiter R, Fuchs D, Hausen A, et al. Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation. 1983;36:650-653.
13. Reibnegger G, Egg D, Fuchs D, et al. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. Arthritis Rheum. 1986;29: 1063-1070.
14. Krause A, Protz H, Goebel KM. Correlation between synovial neopterin and inflammatory activity in rheumatoid arthritis. Ann Rheum Dis. 1989;48:636-640.
15. Harland CC, Whitaker RP, Barron JL, et al. Increased urine neopterin levels in psoriasis. Br J Dermatol. 1992;127:453-457.
16. Lim KL, Muir K, Powell RJ. Urine neopterin: a new parameter for serial monitoring of disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 1994;53:743-748.
17. Fuchs D, Weiss G, Reibnegger G, et al. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci. 1992;29:307-341.
18. Saverymuttu SH. Clinical remission in Crohn's disease - assessment using faecal 111In granulocyte excretion. Digestion. 1986;33:74-79.
19. Florin TH, Paterson EW, Fowler EV, et al. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol. 2006;41:306-311.
20. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13:1100-1105.
21. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion, 16-19.
22. Kjeldsen J, Schaffalitzky de Muckadell OB. Assessment of disease severity and activity in inflammatory bowel disease. Scand J Gastroenterol. 1993;28:1-9.
23. Hodgson HJ, Mazlam MZ. Review article: assessment of drug therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 1991; 5:555-584.
24. Lezin A, Buart S, Smadja D, et al. Tissue inhibitor of metalloproteinase 3, matrix metalloproteinase 9, and neopterin in the cerebrospinal fluid: preferential presence in HTLV type I-infected neurologic patients versus healthy virus carriers. AIDS Res Hum Retroviruses. 2000; 16:965-972.
25. Gomes P, du Boulay C, Smith CL, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986;27:92-95.
26. Andre C, Descos L, Landais P, et al. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut. 1981;22:571-574.
27. de Dombal FT, Softley A. IOIBD report no 1: observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut. 1987;28:474-481.
28. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811-818.
29. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35:231-235.
30. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712.
31. Prior C, Bollbach R, Fuchs D, et al. Urinary neopterin, a marker of clinical activity in patients with Crohn's disease. Clin Chim Acta. 1986;155:11-21.
32. Judmaier G, Meyersbach P, Weiss G, et al. The role of neopterin in assessing disease activity in Crohn's disease: classification and regression trees. Am J Gastroenterol. 1993;88:706-711.
33. Reibnegger G, Bollbach R, Fuchs D, et al. A simple index relating clinical activity in Crohn's disease with T cell activation: hematocrit, frequency of liquid stools and urinary neopterin as parameters. Immunobiology. 1986;173:1-11.
34. Duclos B, Reimund JM, Lang JM, et al. [Mononuclear cell activation in Crohn's disease. Evaluation using serum assay of neopterin and interleukin-2 soluble receptors]. Gastroenterol Clin Biol. 1990;14: 22-27.
35. Reimund JM, Arondel Y, Escalin G, et al. Immune activation and nutritional status in adult Crohn's disease patients. Dig Liver Dis. 2005;37:424-431.
36. Konecny M, Ehrmann J, Bartek J, et al. The level of neopterin in blood serum as one of the possible prognostic markers of Crohn's disease activity. Acta Univ Palacki Olomuc Fac Med. 1996;140:47-48.
37. Giovannoni G, Lai M, Kidd D, et al. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain. 1997;120(Pt 1):1-13.
38. Ghosh S, Chaudhary R, Carpani M, et al. Interfering with interferons in inflammatory bowel disease. Gut. 2006;55:1071-1073.
39. Fais S, Capobianchi MR, Pallone F, et al. Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Gut. 1991;32:403-407.